These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

261 related articles for article (PubMed ID: 25267960)

  • 1. A potential treatment of non-alcoholic fatty liver disease with SIRT1 activators.
    Colak Y; Yesil A; Mutlu HH; Caklili OT; Ulasoglu C; Senates E; Takir M; Kostek O; Yilmaz Y; Yilmaz Enc F; Tasan G; Tuncer I
    J Gastrointestin Liver Dis; 2014 Sep; 23(3):311-9. PubMed ID: 25267960
    [TBL] [Abstract][Full Text] [Related]  

  • 2. SIRT1 activation by methylene blue, a repurposed drug, leads to AMPK-mediated inhibition of steatosis and steatohepatitis.
    Shin SY; Kim TH; Wu H; Choi YH; Kim SG
    Eur J Pharmacol; 2014 Mar; 727():115-24. PubMed ID: 24486702
    [TBL] [Abstract][Full Text] [Related]  

  • 3. SIRT1 as a potential therapeutic target for treatment of nonalcoholic fatty liver disease.
    Colak Y; Ozturk O; Senates E; Tuncer I; Yorulmaz E; Adali G; Doganay L; Enc FY
    Med Sci Monit; 2011 May; 17(5):HY5-9. PubMed ID: 21525818
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Troxerutin improves hepatic lipid homeostasis by restoring NAD(+)-depletion-mediated dysfunction of lipin 1 signaling in high-fat diet-treated mice.
    Zhang ZF; Fan SH; Zheng YL; Lu J; Wu DM; Shan Q; Hu B
    Biochem Pharmacol; 2014 Sep; 91(1):74-86. PubMed ID: 25026599
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Suppression of silent information regulator 1 activity in noncancerous tissues of hepatocellular carcinoma: Possible association with non-B non-C hepatitis pathogenesis.
    Konishi H; Shirabe K; Nakagawara H; Harimoto N; Yamashita Y; Ikegami T; Yoshizumi T; Soejima Y; Oda Y; Maehara Y
    Cancer Sci; 2015 May; 106(5):542-9. PubMed ID: 25736100
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Melatonin Effects on Non-Alcoholic Fatty Liver Disease Are Related to MicroRNA-34a-5p/Sirt1 Axis and Autophagy.
    Stacchiotti A; Grossi I; García-Gómez R; Patel GA; Salvi A; Lavazza A; De Petro G; Monsalve M; Rezzani R
    Cells; 2019 Sep; 8(9):. PubMed ID: 31500354
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Sirtuins and nonalcoholic fatty liver disease.
    Nassir F; Ibdah JA
    World J Gastroenterol; 2016 Dec; 22(46):10084-10092. PubMed ID: 28028356
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Ginsenoside Rb2 Alleviates Hepatic Lipid Accumulation by Restoring Autophagy via Induction of Sirt1 and Activation of AMPK.
    Huang Q; Wang T; Yang L; Wang HY
    Int J Mol Sci; 2017 May; 18(5):. PubMed ID: 28534819
    [TBL] [Abstract][Full Text] [Related]  

  • 9. SIRT1 mediates the role of RNA-binding protein QKI 5 in the synthesis of triglycerides in non-alcoholic fatty liver disease mice via the PPARα/FoxO1 signaling pathway.
    Zhang W; Sun Y; Liu W; Dong J; Chen J
    Int J Mol Med; 2019 Mar; 43(3):1271-1280. PubMed ID: 30664220
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Emerging roles of SIRT1 in fatty liver diseases.
    Ding RB; Bao J; Deng CX
    Int J Biol Sci; 2017; 13(7):852-867. PubMed ID: 28808418
    [TBL] [Abstract][Full Text] [Related]  

  • 11. SIRT1: Harnessing multiple pathways to hinder NAFLD.
    Tian C; Huang R; Xiang M
    Pharmacol Res; 2024 May; 203():107155. PubMed ID: 38527697
    [TBL] [Abstract][Full Text] [Related]  

  • 12. miR-34a/SIRT1/p53 is suppressed by ursodeoxycholic acid in the rat liver and activated by disease severity in human non-alcoholic fatty liver disease.
    Castro RE; Ferreira DM; Afonso MB; Borralho PM; Machado MV; Cortez-Pinto H; Rodrigues CM
    J Hepatol; 2013 Jan; 58(1):119-25. PubMed ID: 22902550
    [TBL] [Abstract][Full Text] [Related]  

  • 13. SIRT1 mediates the effect of GLP-1 receptor agonist exenatide on ameliorating hepatic steatosis.
    Xu F; Li Z; Zheng X; Liu H; Liang H; Xu H; Chen Z; Zeng K; Weng J
    Diabetes; 2014 Nov; 63(11):3637-46. PubMed ID: 24947350
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Inhibition of HMGB1 release via salvianolic acid B-mediated SIRT1 up-regulation protects rats against non-alcoholic fatty liver disease.
    Zeng W; Shan W; Gao L; Gao D; Hu Y; Wang G; Zhang N; Li Z; Tian X; Xu W; Peng J; Ma X; Yao J
    Sci Rep; 2015 Nov; 5():16013. PubMed ID: 26525891
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Garlic essential oil protects against obesity-triggered nonalcoholic fatty liver disease through modulation of lipid metabolism and oxidative stress.
    Lai YS; Chen WC; Ho CT; Lu KH; Lin SH; Tseng HC; Lin SY; Sheen LY
    J Agric Food Chem; 2014 Jun; 62(25):5897-906. PubMed ID: 24857364
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Silibinin Restores NAD⁺ Levels and Induces the SIRT1/AMPK Pathway in Non-Alcoholic Fatty Liver.
    Salomone F; Barbagallo I; Godos J; Lembo V; Currenti W; Cinà D; Avola R; D'Orazio N; Morisco F; Galvano F; Li Volti G
    Nutrients; 2017 Sep; 9(10):. PubMed ID: 28973994
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Role of histone deacetylase on nonalcoholic fatty liver disease.
    Fu S; Yu M; Tan Y; Liu D
    Expert Rev Gastroenterol Hepatol; 2021 Apr; 15(4):353-361. PubMed ID: 33213187
    [No Abstract]   [Full Text] [Related]  

  • 18. The expression of SIRT1 in nonalcoholic fatty liver disease induced by high-fat diet in rats.
    Deng XQ; Chen LL; Li NX
    Liver Int; 2007 Jun; 27(5):708-15. PubMed ID: 17498258
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Protection of hepatocyte mitochondrial function by blueberry juice and probiotics via SIRT1 regulation in non-alcoholic fatty liver disease.
    Ren T; Zhu L; Shen Y; Mou Q; Lin T; Feng H
    Food Funct; 2019 Mar; 10(3):1540-1551. PubMed ID: 30785444
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Metabolic benefits from Sirt1 and Sirt1 activators.
    Chaudhary N; Pfluger PT
    Curr Opin Clin Nutr Metab Care; 2009 Jul; 12(4):431-7. PubMed ID: 19474719
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.